Semaglutide vs Liraglutide
GLP-1 Receptor Agonist · GLP-1 Receptor Agonist
Here is how these two compounds compare, based on published research, not marketing claims.
Semaglutide
The once-weekly GLP-1 agonist with the largest weight loss in head-to-head data and completed cardiovascular outcomes trials across both diabetes and obesity populations.
Liraglutide
The pioneer daily GLP-1 agonist with the longest post-marketing safety record in the class and FDA approval for adolescent obesity (ages 12+).
Semaglutide
4520 studies
39 human trials
FDA-Approved
Liraglutide
5579 studies
36 human trials
FDA-Approved
What it does
Semaglutide
Holds the first FDA approval for a weekly GLP-1 drug with cardiovascular outcomes data. Marketed as Ozempic for type 2 diabetes, Wegovy for weight management, and Rybelsus as an oral tablet. Reduces appetite and slows how fast food leaves the stomach through hypothalamic GLP-1 receptor activation. Two major trials (SUSTAIN-6 in diabetic patients and SELECT in non-diabetic adults with obesity) showed reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death), not just weight or blood sugar. That cardiovascular evidence is what made the GLP-1 class category-shifting in metabolic medicine.
Liraglutide
Tells the brain the body is full and slows how fast the stomach empties. The first daily GLP-1 medication to achieve both diabetes and obesity FDA approvals, with cardiovascular outcomes data from the LEADER trial.
How it works
Semaglutide
A modified copy of GLP-1, a hormone the body releases naturally after eating. It activates the GLP-1 receptor in the brain and gut, which tells the brain the body is full, slows how fast the stomach empties, and helps the pancreas release insulin when blood sugar is high. The modification keeps it active in the body for about a week, instead of the few minutes natural GLP-1 lasts.
Liraglutide
Liraglutide is a modified version of GLP-1, the gut hormone the body releases after eating. It activates the GLP-1 receptor in the brain and gut, suppressing appetite, slowing gastric emptying, and enhancing insulin secretion when blood sugar is high. An acylation modification extends the half-life to approximately 13 hours, allowing once-daily dosing rather than the minutes natural GLP-1 lasts.
How often
Semaglutide
FDA labeling specifies once-weekly subcutaneous injection from a pre-filled pen for the injectable formulation. The SUSTAIN, STEP, and SELECT trial protocols used gradual dose titration over several months, which the FDA labeling notes is associated with improved GI tolerability. Semaglutide is marketed as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as a daily oral formulation for type 2 diabetes.
Liraglutide
FDA labeling specifies once-daily subcutaneous injection from a pre-filled pen for both Victoza (type 2 diabetes) and Saxenda (chronic weight management). The SCALE trial program (weight management) and LEADER trial (cardiovascular outcomes) used daily dosing protocols.
How strong
Semaglutide
Strong appetite suppression. In the STEP obesity trials, average weight loss reached 15-17% at the highest dose over 68 weeks. The effect builds gradually as the dose titrates up over the first months of treatment.
Liraglutide
The pioneer daily GLP-1 medication. FDA-approved for both type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014, including approval down to age 12). The LEADER trial demonstrated cardiovascular benefit in adults with type 2 diabetes and high cardiovascular risk. Established efficacy with the longest post-marketing safety record in the GLP-1 class.
Main tradeoff
Semaglutide
Strong evidence base from large completed Phase III programs (STEP for weight, SUSTAIN and PIONEER for diabetes, SELECT for cardiovascular outcomes). Common side effects are GI: nausea, vomiting, diarrhea, usually transient and dose-dependent. Tirzepatide produces larger average weight loss in head-to-head trials, but semaglutide has the longer cardiovascular outcomes data. Bone mineral density may decrease modestly with significant weight loss; the effect is class-shared with tirzepatide and appears weight-loss-mediated rather than drug-specific (Liu et al. 2026). Particularly relevant for adults at baseline fracture risk.
Liraglutide
Daily injection versus the once-weekly dosing of newer GLP-1 medications (semaglutide, tirzepatide). Head-to-head data from STEP-8 showed semaglutide producing approximately twice the mean body weight reduction compared to liraglutide for the obesity indication. Liraglutide retains the pediatric obesity approval (Saxenda approved for ages 12+) that Wegovy does not have, and carries the longest real-world post-marketing safety record in the GLP-1 class.
Best for
Semaglutide
- Adults with type 2 diabetes seeking glycemic control with cardiovascular outcomes data (SELECT trial)
- Adults with overweight or obesity who want the GLP-1 with the longest real-world safety record
- Clinical contexts prioritizing established cardiovascular outcomes over maximal weight reduction
Liraglutide
- Patients where daily dosing preference or pediatric age (12+) for obesity indication is relevant
- Clinical contexts where the longest post-marketing safety record in the GLP-1 class matters
- Research comparing first-generation versus second-generation GLP-1 receptor agonists
How to choose
A good fit for Semaglutide
- Weekly dosing convenience is a priority over daily injection
- Larger weight loss magnitude matters for the clinical goal (STEP-8 showed approximately twice the weight reduction vs liraglutide)
- Cardiovascular outcomes data in non-diabetic obesity population (SELECT trial) is decision-relevant
- Oral formulation option (Rybelsus) is relevant for the patient
A good fit for Liraglutide
- Pediatric obesity indication (Saxenda approved for ages 12+) is needed
- Longest post-marketing safety record in the GLP-1 class is the priority
- Insurance or formulary access favors liraglutide brands over semaglutide brands
- Patient has established tolerability on liraglutide with no clinical reason to switch
Consider both across time
Semaglutide and liraglutide are both GLP-1 receptor agonists with FDA approvals for type 2 diabetes and chronic weight management. They share the same molecular target and the same class-wide side effect profile. The choice is driven by dosing convenience (weekly vs daily), efficacy magnitude (semaglutide produces approximately twice the weight reduction in head-to-head STEP-8), pediatric access (liraglutide only), post-marketing maturity (liraglutide has the longer record), and insurance coverage. For comparisons against the dual-receptor tirzepatide class, see Semaglutide vs Tirzepatide.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GLP-1 Receptor
- GLP-1 Receptor activates GLP-1 Signaling
- GLP-1 Signaling connects to Appetite + Gastric Emptying
- GLP-1 Signaling connects to Glucose Control
- Appetite + Gastric Emptying connects to Weight + Glycemic Outcomes; Glucose Control connects to Weight + Glycemic Outcomes
- GLP-1 Receptor activates Appetite Suppression
- GLP-1 Receptor activates Gastric Emptying Delay
- GLP-1 Receptor activates Glucose-Dependent Insulin Secretion
- Glucose-Dependent Insulin Secretion connects to Glycemic Control
- Appetite Suppression connects to Weight Reduction; Gastric Emptying Delay connects to Weight Reduction
Semaglutide binds the GLP-1 receptor with extended half-life via albumin binding, allowing once-weekly administration.
Liraglutide binds the GLP-1 receptor with a shorter half-life, requiring daily injection. Pioneer GLP-1 agonist with the longest post-marketing safety record.
Research Evidence
Both compounds have deep evidence bases with completed Phase III programs and cardiovascular outcomes trials. Semaglutide's evidence spans SUSTAIN (T2D), PIONEER (oral T2D), STEP (obesity), and SELECT (CV outcomes in non-diabetic obesity). Liraglutide's evidence spans the earlier LEAD program (T2D) and SCALE (obesity), plus the LEADER cardiovascular outcomes trial. The pivotal head-to-head is STEP-8, which compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily for obesity over 68 weeks: semaglutide produced 15.8% mean body weight reduction versus 6.4% for liraglutide. For evidence depth in the GLP-1 mono-agonist class, semaglutide now leads; for post-marketing maturity and pediatric data, liraglutide retains the longer record.
- 1.
If the primary goal is maximal weight reduction based on clinical trial data, semaglutide has demonstrated substantially greater efficacy (15-17% vs. ~8% mean weight loss).
- 2.
If the clinical context requires the longest available real-world safety record for a GLP-1 agonist, liraglutide has over a decade of post-marketing experience.
- 3.
If dosing convenience and adherence are priorities, semaglutide's weekly dosing offers a meaningful advantage over liraglutide's daily injections.
- 4.
If a patient has not tolerated semaglutide's GI effects, liraglutide's shorter half-life may allow for more granular dose titration, though GI effects remain a class feature.
Key Limitations
- •The SUSTAIN-10 head-to-head trial compared diabetes doses (semaglutide 1mg vs. liraglutide 1.2mg), not the higher weight-management doses, limiting direct efficacy comparisons for obesity.
- •Weight regain after discontinuation is documented for both compounds, raising questions about required treatment duration.
- •Liraglutide's lower weight-loss magnitude may partly reflect dose limitations rather than inherent mechanistic inferiority.
- •Long-term (10+ year) outcomes for semaglutide are not yet available, while liraglutide has accumulated this data.
- •Cost differences between the compounds vary by market and indication, affecting real-world access independently of efficacy.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Semaglutide
"I lost 30+ pounds on Ozempic without changing anything else"
Supported by evidence
"Ozempic face is a real thing. I look ten years older"
Supported by evidence
"The nausea goes away after a few weeks"
Supported by evidence
Liraglutide
"Saxenda stopped working after a few months"
Plausible
"Liraglutide is outdated now that Ozempic exists"
Partially accurate
Safety Comparison
Both share the GLP-1 class gastrointestinal side effect profile (nausea, vomiting, diarrhea, usually transient and dose-dependent). Both carry the FDA boxed warning for thyroid C-cell tumors based on rodent studies. Liraglutide has the longest post-marketing safety record in the GLP-1 class (approved 2010). Semaglutide's post-marketing record is growing (approved 2017). The class-shared bone-loss-with-weight-loss signal (Liu et al. 2026, J Clin Endocrinol Metab) applies to both compounds and correlates with weight loss magnitude rather than specific compound.
Semaglutide
Extensively characterized from STEP, SUSTAIN, PIONEER, and SELECT trials. GI adverse events (nausea, vomiting, diarrhea) are the most common, generally transient. SELECT trial data established cardiovascular benefit. Rare risks include pancreatitis and thyroid C-cell concerns (rodent signal).
Liraglutide
One of the longest real-world safety records among GLP-1 agonists. LEADER trial demonstrated cardiovascular benefit in type 2 diabetes. GI adverse events are common but well-characterized. Long-term safety data extends over a decade of post-marketing use.
What the Research Suggests
Semaglutide and liraglutide share the same receptor target but represent different generations of GLP-1 agonist optimization. Semaglutide offers greater weight-loss efficacy, weekly dosing convenience, and cardiovascular outcome data from SELECT. Liraglutide offers the longest real-world safety record in the GLP-1 class and may serve specific clinical contexts where daily dosing flexibility or a longer-established compound is preferred. The transition from liraglutide to semaglutide as the preferred GLP-1 agonist in clinical practice reflects the efficacy and convenience advantages, but liraglutide retains clinical relevance as a well-characterized alternative.